Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LdT combination with TDF or TAF versus TDF or TAF monotherapy for HBeAg-positive chronic hepatitis B
ChiCTR2100048992Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of telbivudine, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (4 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: HBV DNA negative conversion rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
telbivudinetenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100048992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048992.